Stamulumab
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research[1][2].
Product Specifications
CAS Number
[705287-60-1]
Product Name Alternative
MYO-029
UNSPSC
12352203
Target
TGF-β Receptor
Type
Inhibitory Antibodies
Related Pathways
TGF-beta/Smad
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/stamulumab.html
Purity
95.07
Solubility
H2O
Smiles
[Stamulumab]
Molecular Weight
(142.56 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99588/Stamulumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99588/Stamulumab-SDS-MedChemExpress.pdf
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
